Literature DB >> 20107862

Microtubule targeting agents: from biophysics to proteomics.

D Calligaris1, P Verdier-Pinard, F Devred, C Villard, D Braguer, Daniel Lafitte.   

Abstract

This review explores various aspects of the interaction between microtubule targeting agents and tubulin, including binding site, affinity, and drug resistance. Starting with the basics of tubulin polymerization and microtubule targeting agent binding, we then highlight how the three-dimensional structures of drug-tubulin complexes obtained on stabilized tubulin are seeded by precise biological and biophysical data. New avenues opened by thermodynamics analysis, high throughput screening, and proteomics for the molecular pharmacology of these drugs are presented. The amount of data generated by biophysical, proteomic and cellular techniques shed more light onto the microtubule-tubulin equilibrium and tubulin-drug interaction. Combining these approaches provides new insight into the mechanism of action of known microtubule interacting agents and rapid in-depth characterization of next generation molecules targeting the interaction between microtubules and associated modulators of their dynamics. This will facilitate the design of improved and/or alternative chemotherapies targeting the microtubule cytoskeleton.

Mesh:

Substances:

Year:  2010        PMID: 20107862     DOI: 10.1007/s00018-009-0245-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  146 in total

1.  The 4 A X-ray structure of a tubulin:stathmin-like domain complex.

Authors:  B Gigant; P A Curmi; C Martin-Barbey; E Charbaut; S Lachkar; L Lebeau; S Siavoshian; A Sobel; M Knossow
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

2.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  EndoTAG-1. MediGene.

Authors:  Gunter Schuch
Journal:  Curr Opin Investig Drugs       Date:  2005-12

4.  Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline.

Authors:  V Prakash; S N Timasheff
Journal:  Biochemistry       Date:  1991-01-22       Impact factor: 3.162

5.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Authors:  Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

6.  Synthesis of a photoaffinity analog of taxol as an approach to identify the taxol binding site on microtubules.

Authors:  J M Carboni; V Farina; S Rao; S I Hauck; S B Horwitz; I Ringel
Journal:  J Med Chem       Date:  1993-02-19       Impact factor: 7.446

7.  Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle.

Authors:  C Iancu; S J Mistry; S Arkin; G F Atweh
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

8.  Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.

Authors:  S L Mooberry; G Tien; A H Hernandez; A Plubrukarn; B S Davidson
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

9.  Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin.

Authors:  Lucia Cicchillitti; Roberta Penci; Michela Di Michele; Flavia Filippetti; Domenico Rotilio; Maria Benedetta Donati; Giovanni Scambia; Cristiano Ferlini
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

10.  Stu2p binds tubulin and undergoes an open-to-closed conformational change.

Authors:  Jawdat Al-Bassam; Mark van Breugel; Stephen C Harrison; Anthony Hyman
Journal:  J Cell Biol       Date:  2006-03-27       Impact factor: 10.539

View more
  25 in total

Review 1.  Spatial cycles in G-protein crowd control.

Authors:  Nachiket Vartak; Philippe Bastiaens
Journal:  EMBO J       Date:  2010-08-18       Impact factor: 11.598

Review 2.  Thematic Minireview Series: The State of the Cytoskeleton in 2015.

Authors:  Robert S Fischer; Velia M Fowler
Journal:  J Biol Chem       Date:  2015-05-08       Impact factor: 5.157

3.  Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Authors:  Lori Rice; Christine Pampo; Sharon Lepler; Amyn M Rojiani; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2010-10-23       Impact factor: 3.514

4.  CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.

Authors:  Chang Hoon Moon; Seung Ju Lee; Ho Yong Lee; Le Thi Kim Dung; Wha Ja Cho; HeeJeong Cha; Jeong Woo Park; Young Joo Min
Journal:  Invest New Drugs       Date:  2013-11-08       Impact factor: 3.850

Review 5.  Mechanical modulation of cardiac microtubules.

Authors:  Ed White
Journal:  Pflugers Arch       Date:  2011-04-13       Impact factor: 3.657

6.  Transcriptome analysis on chlorpyrifos detoxification in Uronema marinum (Ciliophora, Oligohymenophorea).

Authors:  Chongnv Wang; William A Bourland; Weijie Mu; Xuming Pan
Journal:  Environ Sci Pollut Res Int       Date:  2018-09-27       Impact factor: 4.223

7.  Screening Anti-Cancer Drugs against Tubulin using Catch-and-Release Electrospray Ionization Mass Spectrometry.

Authors:  Reza Rezaei Darestani; Philip Winter; Elena N Kitova; Jack A Tuszynski; John S Klassen
Journal:  J Am Soc Mass Spectrom       Date:  2016-03-04       Impact factor: 3.109

Review 8.  Microtubule destabilising agents: far more than just antimitotic anticancer drugs.

Authors:  Darcy Bates; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2016-10-18       Impact factor: 4.335

9.  End-binding proteins sensitize microtubules to the action of microtubule-targeting agents.

Authors:  Renu Mohan; Eugene A Katrukha; Harinath Doodhi; Ihor Smal; Erik Meijering; Lukas C Kapitein; Michel O Steinmetz; Anna Akhmanova
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-14       Impact factor: 11.205

10.  Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities.

Authors:  Renaud Prudent; Émilie Vassal-Stermann; Chi-Hung Nguyen; Marjorie Mollaret; Jean Viallet; Agnès Desroches-Castan; Anne Martinez; Caroline Barette; Catherine Pillet; Glaucio Valdameri; Emmanuelle Soleilhac; Attilio Di Pietro; Jean-Jacques Feige; Marc Billaud; Jean-Claude Florent; Laurence Lafanechère
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.